Month: July 2025
Vancouver, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) — St. James Gold Corp. (the “Company” or “St. James”) (TSXV: LORD) (OTCQB: LRDJF) (FSE: BVU3) announced today that its common shares will be reinstated for trading on the TSX Venture Exchange (the “Exchange”) on or about July 29, 2025 as the TSX Venture Exchange has completed its review.
The Company’s financial statements for the period ended March 31, 2025 reflected a working capital deficiency $1,905,769. In order to resolve the deficiency and comply with the Exchange listing requirements, the Company has taken the following steps:The Company has entered into agreements with its largest short-term creditors to issue unsecured notes with a maturity 18 month after issuance to satisfy their indebtedness. A total of $1,580,052.49 of short-term debt is expected to be resolved...
Federal Home Loan Bank of Des Moines Announces Second Quarter 2025 Financial Results, Declares Dividend
Written by Customer Service on . Posted in Dividend Reports And Estimates.
DES MOINES, Iowa, July 25, 2025 (GLOBE NEWSWIRE) —
Second Quarter 2025 HighlightsNet income of $194 million
Affordable Housing Program (AHP) assessments of $21 million
Voluntary community and housing contributions of $43 million
Advances totaled $114.8 billion
Mortgage loans held for portfolio, net totaled $13.2 billion
Letters of credit totaled $17.7 billion
Retained earnings totaled $3.6 billionDividend
The Board of Directors approved a second quarter 2025 dividend to be paid at an annualized rate of 9.75% on average activity-based stock and 6.00% on average membership stock, unchanged from the prior quarter. The Federal Home Loan Bank of Des Moines (the Bank) expects to make dividend payments totaling $145 million on August 12, 2025.
Liquidity Mission
The Bank provides liquidity to its members to support the housing, business,...
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
Written by Customer Service on . Posted in Mergers And Acquisitions.
The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025
ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis
Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026
SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) — Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory (“I&I”) diseases, today announced the completion of its previously announced merger with Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”). The combined company...
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
Written by Customer Service on . Posted in Mergers And Acquisitions.
The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025
ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis
Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026
SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) — Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory (“I&I”) diseases, today announced the completion of its previously announced merger with Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”). The combined company...
LOBO EV Technologies Ltd. Issues Statement Regarding Recent Market Activity
Written by Customer Service on . Posted in Public Companies.
WUXI, China, July 25, 2025 (GLOBE NEWSWIRE) — LOBO EV Technologies Ltd. (Nasdaq: LOBO) (“LOBO” or the “Company”), a developer and manufacturer in electric mobility and intelligent systems, today issued a statement regarding recent trading activity in its common stock.
The Company has observed an increase in trading volume and a corresponding decline in its share price over the past several days. While LOBO does not generally comment on market activity or fluctuations in its stock price, the Company confirms that there have been no material changes to its business operations or strategic direction that would warrant such activity.
The Company continues to operate in the ordinary course of business. Current initiatives, including product development and strategic engagements, are ongoing, and management is not aware of any undisclosed...
Lassonde Industries Inc. Will Hold a Conference Call to Discuss Its Second Quarter 2025 Financial Results
Written by Customer Service on . Posted in Public Companies.
ROUGEMONT, Quebec, July 25, 2025 (GLOBE NEWSWIRE) — Lassonde Industries Inc. (TSX: LAS.A) (“Lassonde” or the “Corporation”) is pleased to announce that it will host a conference call to discuss its financial results for the second quarter of 2025 on Friday, August 8, 2025. Mr. Vince Timpano, Chief Executive Officer, and Mr. Eric Gemme, Chief Financial Officer, will host the call.OPEN TO:
Investors, analysts, and all interested parties
DATE:
Friday, August 8, 2025
TIME:
8:30 a.m. ET
CALL:
647-846-8280 (for overseas participants)1-833-752-3549 (for other North American participants)
A live audio broadcast of the conference call will be available on the Corporation’s website, on the Investors page or here: https://www.gowebcasting.com/14099. The replay of the webcast will...
Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies
Written by Customer Service on . Posted in Public Companies.
Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committed
LA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) — Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that its Board of Directors and executive team have formally initiated a strategic review to explore the potential formation of a dedicated digital asset investment vehicle.
This initiative marks a bold step toward positioning the Company at the forefront of capital innovation, as it evaluates options to diversify its long-term treasury strategy. The prospective subsidiary—which has not yet been formed and remains under active consideration—would operate independently...
Yoshiharu Global Co. Announces Strategic Transition to Vestand Inc.
Written by Customer Service on . Posted in Public Companies.
BUENA PARK, Calif., July 25, 2025 (GLOBE NEWSWIRE) — Yoshiharu Global Co. (NASDAQ: YOSH) (the “Company”), today announced that it plans to change its corporate name to Vestand Inc., and has secured $6.0 million in strategic funding from U.S. and Korean investors to support this transition into a PropTech company. The Company also announced a substantial enhancement of its internal control policy, reinforcing its commitment to transparency and long-term growth as a publicly listed entity.
Corporate Name Change and Business TransitionOn July 10, 2025, the Company’s Board of Directors approved the name change to Vestand Inc., marking its transformation from a traditional restaurant operator into a diversified brand that also includes real estate development and digital asset ventures. The Company has initiated the renaming...
VERSES® Featured in IEEE Spectrum
Written by Customer Service on . Posted in Public Companies.
Spatial Web standards and use cases featured in IEEE flagship publication
VANCOUVER, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) (“VERSES” or the “Company”), a cognitive computing company specializing in next-generation agentic software systems, has been featured in IEEE Spectrum, the flagship publication of the IEEE, the world’s largest professional organization devoted to engineering and the applied sciences.
The article, co-authored by VERSES CEO Gabriel René, addresses questions such as: Why does the Spatial Web matter? How, exactly, can it make the world better? These are answered with five example use cases for the Spatial Web:Energy saving agents at home;
Coordinated mobility standards for autonomous vehicles;
Drones using HSML to read a dynamic map;
Digital...
Intelligent Bio Solutions Inc. Enters Into Agreements to Raise $3.8 Million in Gross Proceeds
Written by Customer Service on . Posted in Public Companies.
Proceeds to Fund Completion of the Company’s 510k Filing with the U.S. FDA for its Fingerprint Drug Screening System
NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced an agreement between the Company and several current warrant holders to exercise (or prepay the exercise price) certain existing warrants to purchase up to 2,023,228 shares of common stock (the “Existing Warrants”) at a reduced exercise price of $1.90 per share.
Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for this transaction.
The resale of the shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to registration statements...